Helminth Clearance as Immunological Preparation for Cancer Treatment: Evidence, Timing, and Clinical Protocol Design
- 1Independent Researcher
Abstract
Background. Helminth infections polarise host immunity toward Th2 and regulatory T cell (Treg) phenotypes, suppressing the Th1/CD8+ cytotoxic T cell responses that underlie both spontaneous anti-tumour immunity and the efficacy of immune checkpoint inhibitor (ICI) therapy. An estimated 1.5 billion people carry soil-transmitted helminths, with hundreds of millions additionally carrying Schistosoma, Strongyloides, or filarial species. In helminth-endemic regions where cancer incidence is rising, a substantial proportion of patients commencing ICI therapy may carry helminth infections that are unscreened, untreated, and immunologically active at the time of treatment initiation. Core question. Does treating helminth infection before initiating cancer immunotherapy allow immune reconstitution sufficient to improve treatment outcomes? This paper assembles evidence bearing on that question, characterises the timing of post-deworming immune recovery, and designs a clinical protocol and pilot trial for testing the intervention. Evidence summary. Post-deworming immune reconstitution studies demonstrate measurable Th1 cytokine increases and Treg normalisation within 6 weeks of praziquantel...
Related
- Geostatistical analysis of baseline prevalence and treatment history drastically reduces the cost of soil-transmitted helminth impact assessment surveys.
- Water, sanitation, and hygiene in soil-transmitted helminth control: A scoping review of evidence gaps across transmission pathways
- A two year clinical, immunological and gut-brain-axis prospective study to predict treatment response to cladribine tablets in relapsing-remitting multiple sclerosis
- Oral microenvironmental dysregulation and female reproductive health: clinical evidence, immunological mechanisms, and bidirectional crosstalk
- Modifiable glymphatic-related brain clearance physiology in humans: a critical narrative review of interventional evidence
BibTeX
@misc{webb2026helminth,
title = {{Helminth Clearance as Immunological Preparation for Cancer Treatment: Evidence, Timing, and Clinical Protocol Design}},
author = {Marcus Webb},
howpublished = {Zenodo (CERN European Organization for Nuclear Research)},
year = {2026},
month = may,
doi = {10.5281/zenodo.20402666},
url = {https://doi.org/10.5281/zenodo.20402666},
note = {CC BY},
}
RIS
TY - UNPB
TI - Helminth Clearance as Immunological Preparation for Cancer Treatment: Evidence, Timing, and Clinical Protocol Design
AU - Marcus Webb
PY - 2026
DA - 2026/05/27
PB - Zenodo (CERN European Organization for Nuclear Research)
DO - 10.5281/zenodo.20402666
UR - https://doi.org/10.5281/zenodo.20402666
AB - Background. Helminth infections polarise host immunity toward Th2 and regulatory T cell (Treg) phenotypes, suppressing the Th1/CD8+ cytotoxic T cell responses that underlie both spontaneous anti-tumour immunity and the efficacy of immune checkpoint inhibitor (ICI) therapy. An estimated 1.5 billion people carry soil-transmitted helminths, with hundreds of millions additionally carrying Schistosoma, Strongyloides, or filarial species. In helminth-endemic regions where cancer incidence is rising, a substantial proportion of patients commencing ICI therapy may carry helminth infections that are unscreened, untreated, and immunologically active at the time of treatment initiation. Core question. Does treating helminth infection before initiating cancer immunotherapy allow immune reconstitution sufficient to improve treatment outcomes? This paper assembles evidence bearing on that question, characterises the timing of post-deworming immune recovery, and designs a clinical protocol and pilot trial for testing the intervention. Evidence summary. Post-deworming immune reconstitution studies demonstrate measurable Th1 cytokine increases and Treg normalisation within 6 weeks of praziquantel...
ER -